{"id":"f4ddbec1-7d1a-51af-b8ce-47715fa1ae16","stable_key":"ca8e9e6a-6953-51ec-b712-2b06398a416d:ra-microsome-hydroxylation","predicate":"reported_relationship","statement":"Microsomal RA hydroxylation products were assigned, with additional GSH adducts and a separate Michael-addition product.","claim_class":"observational","status":"source_recorded","evidence_grade":"ungraded","direction":"neutral","is_public":true,"mechanism_event_id":"b36cfc93-f094-5016-ae83-c306fe571b07","mechanism_event_label":"Microsomal RA hydroxylation products were assigned, with additional GSH adducts and a separate Michael-addition product.","subject":{"id":"6072a4ae-d563-5466-a1b2-6d280255d346","slug":"rosmarinic-acid","display_name":"Rosmarinic acid","entity_type_key":"small_molecule"},"object":{"id":"bad9e015-b0ed-5595-a817-9420005e9f22","slug":"ra-hydroxylated-metabolites","display_name":"Hydroxylated rosmarinic-acid metabolites","entity_type_key":"chemical_species"},"evidence_count":1,"mechanism_event":{"id":"b36cfc93-f094-5016-ae83-c306fe571b07","stable_key":"ca8e9e6a-6953-51ec-b712-2b06398a416d:ra-microsome-hydroxylation-event","event_type":"experimental_observation","label":"Microsomal RA hydroxylation products were assigned, with additional GSH adducts and a separate Michael-addition product.","description":"### ra-microsome-hydroxylation\n\nMicrosomal RA hydroxylation products were assigned, with additional GSH adducts and a separate Michael-addition product.\nThese are structural pathway assignments from trapping, not measured clinical injury.\nModel and exposure: Human liver microsomes; M10–M14 and M6 assignments.\nLimitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.\nReference: Characterization of the metabolites of rosmarinic acid in human liver microsomes using liquid chromatography combined with electrospray ionization tandem mass spectrometry. | 2020 | https://pubmed.ncbi.nlm.nih.gov/32012312/ | https://doi.org/10.1002/bmc.4806 | Access: Indexed primary abstract/metadata only; unextracted doses, figures and methods remain unknown.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"6072a4ae-d563-5466-a1b2-6d280255d346","slug":"rosmarinic-acid","display_name":"Rosmarinic acid","entity_type_key":"small_molecule"},"role":"recorded factor","stoichiometry":null,"state_label":"as reported","sequence_order":0,"notes":""},{"entity":{"id":"bad9e015-b0ed-5595-a817-9420005e9f22","slug":"ra-hydroxylated-metabolites","display_name":"Hydroxylated rosmarinic-acid metabolites","entity_type_key":"chemical_species"},"role":"measured outcome","stoichiometry":null,"state_label":"not_reported","sequence_order":1,"notes":""},{"entity":{"id":"b44c9e27-4bbb-52d3-a022-14cddded5073","slug":"glutathione","display_name":"GSH","entity_type_key":"small_molecule"},"role":"adduct-forming reactant","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""}]},"contexts":[{"dimension":"evidence_access","value_text":"Indexed primary abstract/metadata only; unextracted doses, figures and methods remain unknown.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Human liver microsomes; M10–M14 and M6 assignments.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"interpretation_status","value_text":"Recorded from source with stated access limits; ungraded, not independent replication.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Rosmarinic acid collection; exact intervention and molecular form govern interpretation.","comparator":null,"unit":null,"notes":"","entity":{"slug":"rosmarinic-acid","display_name":"Rosmarinic acid","entity_type_key":"small_molecule"}},{"dimension":"plain_language","value_text":"Microsomal RA hydroxylation products were assigned, with additional GSH adducts and a separate Michael-addition product.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Characterization of the metabolites of rosmarinic acid in human liver microsomes using liquid chromatography combined with electrospray ionization tandem mass spectrometry. | https://pubmed.ncbi.nlm.nih.gov/32012312/ | https://doi.org/10.1002/bmc.4806","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"source_locator","value_text":"Reviewed reference ra-microsome-hydroxylation; These are structural pathway assignments from trapping, not measured clinical injury.","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"2efee5c6-d645-56b9-a990-0ef3952616d0","evidence_kind":"source_excerpt","locator":"Lines 161-167","start_line":161,"end_line":167,"excerpt":"### ra-microsome-hydroxylation\n\nMicrosomal RA hydroxylation products were assigned, with additional GSH adducts and a separate Michael-addition product.\nThese are structural pathway assignments from trapping, not measured clinical injury.\nModel and exposure: Human liver microsomes; M10–M14 and M6 assignments.\nLimitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.\nReference: Characterization of the metabolites of rosmarinic acid in human liver microsomes using liquid chromatography combined with electrospray ionization tandem mass spectrometry. | 2020 | https://pubmed.ncbi.nlm.nih.gov/32012312/ | https://doi.org/10.1002/bmc.4806 | Access: Indexed primary abstract/metadata only; unextracted doses, figures and methods remain unknown.","model_system":"Human liver microsomes; M10–M14 and M6 assignments.","directness":"reported_statement","verification_status":"source_recorded","notes":"Original paraphrase in the retained reviewed reference, not a verbatim primary-paper quotation. Access level is explicit.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"606cff22-a6ed-59cd-a84d-87f44c59dc25","stable_key":"import-ca8e9e6a-6953-51ec-b712-2b06398a416d","title":"Rosmarinic acid: detailed mechanisms of action (reviewed 10 October 2026)","document_type":"imported_text","citation_label":"AI-assisted original curation of primary studies; claim-local access and experimental limitations stated. Includes original-draft correction history. No independent replication claimed.","file_path":"","sha256":"684b4eab1dc2c0057f679109770af0de9340af5cd933377b590298cf8a752956","revision_id":"4028d9c5-fb17-54c5-b72c-c6d21678a832","review_status":"source_recorded","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}